Homrich & Berg decreased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 27.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,529 shares of the company’s stock after selling 585 shares during the period. Homrich & Berg’s holdings in Henry Schein were worth $280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. SpiderRock Advisors LLC bought a new position in shares of Henry Schein during the first quarter valued at $102,000. Lee Financial Co bought a new position in shares of Henry Schein during the second quarter valued at $161,000. Westside Investment Management Inc. bought a new position in shares of Henry Schein during the first quarter valued at $168,000. JNBA Financial Advisors bought a new position in shares of Henry Schein during the first quarter valued at $170,000. Finally, Peddock Capital Advisors LLC raised its position in shares of Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock valued at $186,000 after buying an additional 247 shares during the period. 89.08% of the stock is owned by institutional investors.

Henry Schein, Inc. (HSIC) opened at 169.62 on Thursday. Henry Schein, Inc. has a 1-year low of $146.23 and a 1-year high of $186.99. The stock has a 50 day moving average of $177.99 and a 200 day moving average of $175.84. The stock has a market cap of $13.41 billion, a price-to-earnings ratio of 24.79 and a beta of 1.09. Henry Schein’s stock is scheduled to split before the market opens on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly created shares will be payable to shareholders after the market closes on Thursday, September 14th.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.73 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the business earned $1.64 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. Equities analysts expect that Henry Schein, Inc. will post $7.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Shares Sold by Homrich & Berg” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/08/31/henry-schein-inc-hsic-shares-sold-by-homrich-berg.html.

Several research analysts have weighed in on HSIC shares. Zacks Investment Research raised shares of Henry Schein from a “hold” rating to a “buy” rating and set a $206.00 target price for the company in a research note on Friday, June 16th. Northcoast Research raised shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 target price for the company in a research note on Monday, August 7th. Jefferies Group LLC reaffirmed a “hold” rating and set a $177.00 target price on shares of Henry Schein in a research note on Friday, July 21st. Credit Suisse Group reaffirmed a “hold” rating and set a $160.00 target price on shares of Henry Schein in a research note on Thursday, July 13th. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Henry Schein in a research note on Thursday, July 6th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $186.50.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.